References
- Brunel JM, Salmi C, Loncle C, . Squalamine: a polyvalent drug of the future? Curr Cancer Drug Targets 2005; 5: 267–272.
- Salmi C, Brunel JM. Therapeutic potential of cationic steroid antibacterials. Expert Opin Investig Drugs 2007; 16: 1143–1157.
- Herbst RS, Hammond LA, Carbone DP, . A phase I/IIA trial of continuous five-day infusion of squalamine lactate [MSI-1256F] plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 15: 4108–4115.
- Alhanout K, Brunel JM, Raoult D, . In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J Antimicrob Chemother 2009; 64: 810–814.
- Salmi C, Loncle C, Vidal N, . Squalamine: an appropriate strategy against the emergence of multidrug resistant gram-negative bacteria? PLoS ONE 2008; 3: e2765.
- Fisher BT, Zaoutis TE. Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs 2008; 10: 281–298.
- Klepser ME. Candida resistance and its clinical relevance. Pharmacotherapy 2006; 26: 68–75.
- Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243–260.
- Montravers P, Jabbour K. Clinical consequences of resistant Candida infections in intensive care. Int J Antimicrob Agents 2006; 27: 1–6.
- Salmi C, Loncle C, Vidal N, . Antimicrobial activities of 3-amino- and polyaminosterol analogues of squalamine and trodusquemine. J Enzyme Inhib Med Chem 2008; 23: 860–865.
- Pryce TM, Palladino S, Kay ID, . Rapid identification of fungi by sequencing the ITS1 and ITS2 regions using an automated capillary electrophoresis system. Med Myco 2003; 41: 369–381.
- NCCLS WPU2. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard M27-A2. Drug Chem Toxicol 2002; 32: 283–292.
- Leszczynska K, Namiot A, Fein DE, . Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9: 187.
- Izgu F, Altinbay D, Tureli AE. In vitro susceptibilities of Candida spp. to Panomycocin, a novel exo-beta-1,3-glucanase isolated from Pichia anomala NCYC 434. Microbiol Immunol 2007; 51: 797–803.
- Pfaller MA, Messer SA, Boyken L, . In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201–205.
- Kikuchi K, Bernard EM, Sadownik A, . Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother 1997;41: 1433–1438.
- Chin JN, Jones RN, Sader HS, . Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365–370.
- Nogueira RC, Oliveira-Costa JF, de Sa MS, . Early toxicity screening and selection of lead compounds for parasitic diseases. Curr Drug Targets 2009; 10: 291–298.